Restoring Balance: What the FDA's Peptide Announcement Could Mean for Patient Access and Safety Empower Pharmacy FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of After being placed into FDA Category 2 in 2023, several widely discussed peptides faced restricted pathways for regulated compounding. This shift pushed demand toward unregulated markets and created significant uncertainty across the FDA Removes 12 Peptides from 503A Category 2 Newtropin HHS Secretary RFK Jr. just dropped major news: the FDA is removing 12 peptides from its restrictive Category 2 list reversing the 2023 crackdown that shut down compounding pharmacies and fueled